New strategies based on nucleic acid technologies are being exploited to treat chronic hepatitis B—a pilot clinical study of antisense oligonucleotide treatment shows the potential promise of this approach.
References
Xia, Y. & Liang, T. J. Gastroenterology 156, 311–324 (2019).
Raimondo, G. et al. J. Hepatol. 71, 397–408 (2019).
Loomba, R., Liang, T. J. & Hepatitis, B. Gastroenterology 152, 1297–1309 (2017).
Chen, C. J. & Yang, H. I. J. Gastroenterol. Hepatol. 26, 628–638 (2011).
Yuen, M.-F. et al. Nat. Med. https://doi.org/10.1038/s41591-021-01513-4 (2021).
van den Berg, F. et al. Viruses 12, 851 (2020).
Werle-Lapostolle, B. et al. Gastroenterology 126, 1750–1758 (2004).
Allweiss, L. & Dandri, M. Viruses 9, 156 (2017).
Bertoletti, A. & Ferrari, C. Gut 61, 1754–1764 (2012).
Vaillant, A. Gastroenterology 160, 967–968 (2021).
Junt, T. & Barchet, W. Nat. Rev. Immunol. 15, 529–544 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Liang, T.J. Hepatitis B: a new weapon against an old enemy. Nat Med 27, 1672–1673 (2021). https://doi.org/10.1038/s41591-021-01512-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-021-01512-5
- Springer Nature America, Inc.